Over the last 10 years GlaxoSmithKline has grown to become New Zealand's largest supplier of asthma medicines.

Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself up for the start of another busy week.

The British pharma said its shot didn’t meet the efficacy goals of a Phase 2 study. Elsewhere, Zealand reported more obesity ...

Questions remain about GSK’s ability to come up with new drugs and litigation over the antacid Zantac, and the stock still ...

After several years of anticipation, it’s a new GSK. And so far, the results look pretty good. The company, with facilities in Collegeville and Valley Forge, reported positive second quarter ...

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...

Around 15,000 Kiwis living with chronic obstructive pulmonary disease (COPD), the fourth leading cause of death in NZ, could benefit from the funding of a new medicine that will allow them to switch ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Several Big Pharmas took home trophies at the annual Fierce Pharma Marketing Awards on Wednesday night. | Several Big Pharmas took home trophies at the annual Fierce Pharma Marketing Awards on ...

GSK's specialty medicines segment showed strong performance, growing over 20% due to successful new launches. Additionally, GSK is currently undervalued, trading at £16.1, significantly below the ...

Analyst Graham Parry from Bank of America Securities maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) and keeping the ...